SURVYR
13F +22% · DUQUESNE Institutional Filing Alert

Duquesne Family Office (Stanley Druckenmiller) added to TEVA (+22% shares QoQ · 8.2% of 13F portfolio)

Form 13F-HR institutional holdings disclosure · Filed 2026-10-16

Duquesne Holdings › All Filing Alerts › SEC Filing ↗

TEVA

Teva Pharmaceutical Industries Limited
$39.97
−$0.42 (1.04%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-7%+23%+54%+84%+114%Oct 2025Oct 2026Apr 202652w high $42.0252w low $19.23
TEVASPY
Wall St. Highest PT $55.00 (+37.6%) Wall St. Avg PT $47.58 (+19.0%)
$20$29$38$47$57POC $34Hi $55Avg $48
Underwater Drawdown %Max DD -21.8%Current -3.7%
0.0%-21.8%
Relative Strength vs SPY+89.9% vs SPYOutperforming
+114%0%-114%
1W
−$0.65 (1.60%)
1M
+$1.09 (2.80%)
3M
+$5.26 (15.15%)
6M
+$4.59 (12.97%)
YTD
+$8.76 (28.07%)
1Y
+$20.19 (102.07%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
13 analysts · mean score 1.46
1 = Strong Buy · 5 = Sell
Strong Buy431%
Buy862%
Hold18%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$39.97
Average target$47.58
+$7.61 (+19.0%) upsideaverage target vs current price
CurrentAverageMedian
Low$42.00
Median$47.50
High$55.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-15 · Barclays reiterated Overweight on TEVA
Reiterated
2026-10-12 · JP Morgan reiterated Overweight on TEVA
Initiated
2026-10-01 · TD Cowen started covering TEVA at Buy
Initiated
2026-09-23 · Oppenheimer started covering TEVA at Outperform
Initiated
2026-09-09 · Leerink Partners started covering TEVA at Outperform
Reiterated
2026-09-04 · UBS reiterated Buy on TEVA
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$47.1B
P/E (last 12 months)67.3
P/E (next 12 months, estimated)13.1
52-week range$19.23 – $42.02
Revenue growth (latest quarter vs a year ago)-0.8%
Dividend yieldNo dividend
Analyst consensusStrong Buy (12)
Average analyst price target$47.58 (+19%)

What they do

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. The company also focuses on the central nervous system (CNS), respiratory, oncology.

Healthcare · Drug Manufacturers - Specialty & Generic
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for TEVA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

TEVA earningsNext report in 6 days
Next report · quarter Sep 2026
Tue Nov 3, 2026Before the open
EPS consensus$0.73 range $0.60–$0.89
Revenue consensus$4.2B 11 analysts
Last 4 quarters · EPS vs estimate
Jul 29, 2026$0.02est $0.11−81.5%Below estimates
Apr 29, 2026$0.53est $0.46+16.2%Above estimates
Jan 28, 2026$0.96est $0.64+50.2%Above estimates
Nov 5, 2025$0.78est $0.67+15.7%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-27 18:04:07 ET
24-1125-0125-0525-0725-1126-0126-0426-070.000.96
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$4.1B-0.8%
2026-03-31$4.0B–
2025-12-31$4.7B–
2025-09-30$4.5B–
2025-06-30$4.2B–

Recent dividends

2017-11-27: $0.085 · 2017-08-25: $0.085 · 2017-06-01: $0.340 · 2017-02-28: $0.340 · 2016-12-01: $0.340 · 2016-08-18: $0.340 · 2016-05-20: $0.340 · 2016-02-25: $0.340

News & catalysts

More news
Sector Update: Healthcare Stocks Decline Tuesday Afternoon
MT Newswires · Oct 27
Teva Pharmaceutical Industries Unit Buys Rights to BXCL501 From BioXcel Therapeutics
MT Newswires · Oct 27
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
GlobeNewswire · Oct 27
Teva Pharmaceutical Industries (TEVA) Secured WELTRUZA Approval, Is It Still 16% Below Fair Value?
Simply Wall St. · Oct 23
Dr. Reddy's Laboratories Q2 Earnings Call Highlights
MarketBeat · Oct 23
Rating changes
Reiterated
2026-10-15 · Barclays reiterated Overweight on TEVA
Reiterated
2026-10-12 · JP Morgan reiterated Overweight on TEVA
Initiated
2026-10-01 · TD Cowen started covering TEVA at Buy
Initiated
2026-09-23 · Oppenheimer started covering TEVA at Outperform
Initiated
2026-09-09 · Leerink Partners started covering TEVA at Outperform
Reiterated
2026-09-04 · UBS reiterated Buy on TEVA

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Mignone Roberto
Director · 2026-09-18
Sell
$14.4M
Savage Brian
Interim Chief Legal Officer · 2026-09-18
Sell
$12.2K
Savage Brian
Interim Chief Legal Officer · 2026-09-18
Sell
$98.8K
Savage Brian
Interim Chief Legal Officer · 2026-09-18
Sell
$174.2K
Satchi-Fainaro Ronit
Director · 2026-08-21
Sell
$15.5K
Weiss Amir
Chief Accounting Officer · 2026-08-21
Sell
$94.1K
Weiss Amir
Chief Accounting Officer · 2026-08-21
Sell
$261.2K
Lippman Evan
EVP, Business Development · 2026-08-17
Sell
$680.3K
Zaks Tal Zvi
Director · 2026-08-05
Sell
$593
Hughes Eric A
See "Remarks" · 2026-08-03
Sell
$892.1K
Jover Placid
See "Remarks" · 2026-08-03
Sell
$447.4K

Stats refreshed 2026-10-27 18:04:07 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026